| Name | Title | Contact Details |
|---|
BlissCo Cannabis Corp. (CSE: BLIS) (FRA: GQ4B) is an ACMPR licensed producer and future distributor of ultra-premium cannabis. The company sits at the heart of an international ecosystem and is focused on the success of its domestic and global partnerships. BlissCo leverages the latest technology and is continuously developing its network of top-tier industry experts to drive the success of its brand and channels, moving premium Canadian cannabis to local and international markets. BlissCo is backed by an experienced team that is deeply in tune and integrated with industry partners and BlissCo`s future patients and customers.
Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical
Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action. The Company's lead product, SUSTOL™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration during the fourth quarter of 2014. Heron Therapeutics' core Biochronomer technology, on which SUSTOL and its other products are based, consists of bioerodible polymers designed to release drugs over a defined period of time. The Company has completed over 100 in vivo and in vitro studies demonstrating that its Biochronomer technology is potentially applicable to a range of therapeutic areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. Heron Therapeutics has also completed comprehensive animal and human toxicology studies that have established that its Biochronomer polymers are generally well tolerated. Furthermore, the Company's Biochronomer technology can be designed to deliver drugs over periods varying from days to several months. In addition to its lead drug candidate SUSTOL, Heron Therapeutics has a pipeline of other product candidates that use the Biochronomer technology.
Cansortium Holdings utilizes a unique combination of capital and expertise in making strategic investments to help launch mature and professional cannabis markets. As global regulations evolve, Consortium Holdings is well-positioned to expand its presence in the U.S. and Puerto Rico.
Breakthrough Behavior provides applied behavior analysis (ABA) therapy, speech therapy, and psychological testing services to children and young adults with autism and other developmental disabilities.